Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul>
<li>Arrowhead Pharmaceuticals is progressing through a pivotal transitional phase marked by the recent commercial launch of REDEMPLO, an FDA-approved RNAi-based therapy for familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely elevated triglyceride levels.</li>
<li>The U.S. launch initiated in late 2025 has gained traction, with over 400 prescriptions written within approximately five months and a patient base predominantly naive to similar APOC3 inhibitors.</li>
<li>The company’s pricing strategy—set at a wholesale acquisition cost (WAC) of $45,000 annually, a premium over competitors—is supported by clinical data signaling superior triglyceride reduction, safety, and dosing convenience.</li>
</ul>


Arrowhead Pharmaceuticals is progressing through a pivotal transitional phase marked by the recent commercial launch of REDEMPLO, an FDA-approved RNAi-based therapy for familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely elevated triglyceride levels.
The U.S. launch initiated in late 2025 has gained traction, with over 400 prescriptions written within approximately five months and a patient base predominantly naive to similar APOC3 inhibitors.
The company’s pricing strategy—set at a wholesale acquisition cost (WAC) of $45,000 annually, a premium over competitors—is supported by clinical data signaling superior triglyceride reduction, safety, and dosing convenience.


Arrowhead Pharmaceuticals’ $45,000 REDEMPLO Launch: Can RNAi Scale Beyond Rare Disease?